Measuring FGF23 breakdown in blood across stages of chronic kidney disease
Compares FGF23 breakdown in blood samples from men with chronic kidney disease.
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Saint Etienne
- Where
- Saint-Etienne, FranceSee the site
- Trial code
- Registry title
- Association Between Chronic Kidney Disease Stage and Circulating FGF23 Cleavage Intensity in Patients With Chronic Kidney Disease
- Status
- Not yet recruiting
- People taking part
- 80 people, planned
- Started
- Sept 2026
- Expected to end
- May 2027
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Blood sampling and biomarker assessment
- Record updated
- 31 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 55 to 75 with chronic kidney disease at stage 3a to 5. Extra blood tubes are taken during routine care.
- Age
- 55 to 75 years
- Sex
- Men only
- Disease stage
- Chronic kidney disease stage 3a to 5, based on the most recent kidney function (GFR) measurement. The study plans 20 people per stage.
Main reasons for not taking part
- Active cancer
- Cancer in remission for less than 5 years
- Cancer in remission for more than 5 years with cancer treatment still ongoing
- Taking part in another study on treatments for the disease
- Being under legal guardianship or conservatorship
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- MRC stage 3a-5 based on the most recent GFR measurement
- Patient enrolled in or eligible for a social security program
- Patients who have received informed consent regarding the study and have given their verbal consent to participate
Who cannot take part
- Active cancer or a history of cancer in remission for less than 5 years, or a history of cancer in remission for more than 5 years with specific oncological treatment still ongoing
- Participation in another study related to treatments for the disease
- Patients under legal guardianship (legal guardianship or conservatorship)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 75 years old?
Where in France
- Chu de Saint EtienneSaint-Etienne, FranceContact: Christophe MARIAT, PHDNo longer taking part
About the trial
What the trial wants to find out
This cross-sectional proof-of-concept study aims to investigate the relationship between chronic kidney disease (CKD) severity and circulating FGF23 (fibroblast growth factor 23) cleavage intensity estimated by the iFGF23/cFGF23 ratio. Eighty male patients aged 55-75 years with CKD stages 3a to 5 will be included (20 per stage). Blood samples obtained during routine nephrology care will be supplemented by two additional tubes to measure iFGF23, cFGF23, hepcidin, erythropoietin, 1,25-vitamin D and TRAP5b. The primary endpoint is the iFGF23/cFGF23 ratio. Secondary analyses will evaluate the associations between FGF23 forms and renal, hematological, iron metabolism and mineral bone parameters. This study will provide the first human data on FGF23 cleavage alterations across CKD stages and may identify novel biomarkers for anemia and cardiovascular complications.
The 4 groups in the trial
- Patients CKD 3aExisting treatment, for comparison
Patients with stage 3a kidney disease during a nephrology consultation with an investigator (inclusion visit).
Treatment: Blood sampling and biomarker assessment
- Patients CKD 3bExisting treatment, for comparison
Patients with stage 3b kidney disease during a nephrology consultation with an investigator (inclusion visit).
Treatment: Blood sampling and biomarker assessment
- Patients CKD 4Existing treatment, for comparison
Patients with stage 3b kidney disease during a nephrology consultation with an investigator (inclusion visit).
Treatment: Blood sampling and biomarker assessment
- Patients CKD 5Existing treatment, for comparison
Patients with stage 5 kidney disease during a nephrology consultation with an investigator (inclusion visit).
Treatment: Blood sampling and biomarker assessment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Association Between Chronic Kidney Disease Stage and Circulating FGF23 Cleavage Intensity in Patients With Chronic Kidney Disease
- Plain-language title
- Measuring FGF23 breakdown in blood across stages of chronic kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07676526, who can take part
- Record updated
- 31 July 2026